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ABSTRACT 
Since breastfeeding is not always possible, infant formulas (IF) are supplemented 
with prebiotic oligosaccharides, such as galactooligosaccharides (GOS) and/or 
fructooligosaccharides (FOS) to exert similar effects to those of the breast milk. 
Nowadays, a great number of infant formulas enriched with prebiotics are disposal in the 
market, however there are scarce data about their composition. In this study, the combined 
use of two chromatographic methods (GC-FID and HPLC-RID) has been used for the 
quantification of carbohydrates present in commercial infant formulas. According to the 
results obtained by GC-FID for products containing prebiotics, the content of FOS, GOS 
and GOS/FOS was in the ranges of 1.6-5.0, 2.8-3.8 and 4.8-5.3 g/100 g of product, 
respectively. HPLC-RID analysis allowed quantification of maltodextrins with DP up to 
19. The methodology proposed here may be used for routine quality control of infant 
formula and other food ingredients containing prebiotics.  
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 1. Introduction 
Although human milk is considered the best food to satisfy the nutritional newborn 
infant's needs, there are some situations where breastfeeding must be interrupted and 
infants are fed with infant formula (IF) or cases where mothers cannot produce enough 
milk to supply all of their baby’s nutritional needs and they combine breast and formula 
feeding. The knowledge gained on chemical composition and biological properties of 
human milk allows adapting the composition of IFs to meet the nutritional needs of the 
newborns.  
Human milk contains 8-13 g/L of a complex mixture of oligosaccharides which is 
about 20-fold higher than those of bovine milk (Urashima, Taufik, Fukuda, & Asakuma, 
2013). This is one of the factors that explain, at least in part, the higher level of intestinal 
bifidobacteria and lactobacilli, as well as, the lower incidence of bacterial infections found 
in breast-fed infants (Barile & Rastall, 2013). 
Since Gibson and Roberfroid (1995) introduced the concept of prebiotics as “non-
digestible oligosaccharides that reach the colon without being hydrolysed and are 
selectively metabolized by health-positive bacteria such as bifidobacteria and lactobacilli 
thereby exerting a beneficial effect on the host health”, extensive research has been carried 
out to identify prebiotic components. A growing number of in vitro and in vivo studies also 
show that prebiotics could induce beneficial physiological effects in the colon and also in 
extra-intestinal compartments or contribute towards the reduction of the risk of dysbiosis 
and associated intestinal and systemic pathologies (Roberfroid et al., 2010). Several other 
studies strongly suggest that human milk oligosaccharides (HMOs) act as prebiotics (Bode, 
2009; Engfer, Stahl, Finke, Sawatzki, & Daniel, 2000) and have a wide range of biological 
activities. However, as HMOs are very complex glycans, their production at industrial 
scale is very difficult (Bode, 2009).  
Only the enzymatic synthesis of some prebiotic such as galactooligosaccharides (GOS) 
and fructooligosaccharides (FOS) is a feasible alternative to produce them in the food 
industry. Particularly, it has been shown that the addition of different amounts of GOS, 
FOS or GOS/FOS mixtures to IF stimulates the growth of bifidobacteria and lactobacilli 
(Ben et al., 2008; Boehm et al., 2002; Moro et al., 2002), produces changes in the short 
chain fatty acids making the profile of these acids closer to that observed in breast-fed 
infants (Knol et al., 2005), improves the stool characteristics (frequency, pH and softening) 
(Ben et al., 2008; Fanaro et al., 2005;  Moro et al., 2002) and reduces the incidence of 
allergic manifestations and infections during the first two years of life (Arslanoglu et al., 
2008). 
IFs are composed basically by carbohydrates (54 – 61 g/100 g of product) and proteins 
(11 - 15 g/100 g of product). Depending on the type of IF, sugars such as lactose, corn 
syrup, sucrose or starches have been successfully used as a source of carbohydrates 
(Morales, Olano, & Corzo, 2004). Besides, in the last years, prebiotic oligosaccharides 
have been added to IFs to mimic the benefits attributed to HMOs (Barile & Rastall, 2013; 
Braegger et al., 2011; Cilla, Lacomba, Garcia-Llatas, & Alegria, 2012). Despite the 
increasing use of prebiotics in IF production, there are scarce data about their prebiotic 
composition. In this work, a study on the carbohydrate composition of 24 commercial IFs, 
selected as representative of the Spanish market, has been carried out. Special attention has 
been paid to the determination of prebiotic carbohydrates. 
 
2. Materials and methods 
2.1. Reference substances and samples 
Analytical reference substances such as fructose, galactose, glucose, myo-inositol, 
lactose, maltulose, maltose, kestose, nystose and maltodextrins with a degree of 
polymerization (DP) from 2 to 5 were purchased from Sigma (St. Louis, MO, USA).  
Raftilose® and Wako® FOS were from Orafti (ORAFTI, Barcelona, Spain) and Wako 
(Chemical Industries, Osaka, Japan), respectively. Vivinal® GOS were from Domo 
(Friesland Campina Domo, Amersfoort, Netherlands). 
Twenty four IFs were purchased from several Spanish chemist’s, corresponding to 
starting and follow-up formulas without prebiotics (n=8), 4 with lactose (C) and 4 lactose 
free (LF), and prebiotic-enriched IF (n=16), 3 with FOS (PFOS), 7 with GOS (PGOS), and 
6 with mixtures of GOS/FOS (PGOS/FOS). Table 1 shows their carbohydrate composition 
as indicated on the product labels. All samples were analysed before their expiry date and 
all determinations were done in duplicate.  
 
2.2. Determination of carbohydrates 
Before chromatographic analysis, fat and protein interfering materials were 
removed by precipitation, using Carrez reagents (Moreno, Olano, Santa-Maria, & Corzo, 
1999). 
Carbohydrate (monosaccharides, disaccharides, GOS and FOS) quantification was 
carried out by GC-FID, following the method of Montilla, van de Lagemaat, Olano and del 
Castillo (2006). Analysis of maltodextrins were performed by HPLC-RID according to 
Corzo-Martínez, Copoví, Olano, Moreno and Montilla (2013).  
To quantify GOS in the IFs containing maltodextrins and to avoid interference in 
the GC analysis, samples were incubated at 37°C for 24 h with α-amyloglucosidase 
(Megazyme©3300, Bray Co. Wicklow, Ireland) (330 U/mL IF reconstituted at 100 mg/mL) 
in order to remove them.  
 
3. Results and discussion 
 The GC method of Montilla et al. (2006) has been used in this study to determine 
carbohydrate composition of commercial IFs. The repeatability was calculated using an IF 
containing prebiotics. Four replicates of this formula were analysed daily during the 
following 4 days (Table 2). As it can be observed, the repeatability was acceptable for all 
carbohydrates measured with relative standard deviations below 10%, with the exception 
for hexa and heptasaccharides (12,3%), similar results were obtained by Montilla et al. 
(2006). GC profiles of the carbohydrates found in the starting and follow–up IFs with 
prebiotics are depicted in Figure 1. The used GC method allowed the quantification of the 
monosaccharides fructose, galactose and glucose, myo-inositol, the disaccharides sucrose 
and lactose, and the prebiotic oligosaccharides GOS and FOS with a degree of 
polymerization (DP) of up to 7. Figure 1 also shows the carbohydrate profiles of 
commercial Vivinal®GOS (Figure 1A) and Raftilose®FOS (Figure 1B), commonly added 
to IF products. It can be observed that the chromatographic profiles of commercial GOS 
and FOS were similar to those found in IFs, containing these carbohydrates. The 
chromatographic profiles of IFs containing GOS and maltodextrins after hydrolysis using 
α-amyloglucosidase are also shown in Figure 2. In this case, the previous hydrolysis of 
maltodextrins allowed the quantification of GOS. 
Table 3 shows the carbohydrate composition of the analysed commercial IFs. In 
general, fructose, glucose and galactose, were detected in the majority of the studied IFs. 
Their concentrations were quite similar to those previously found in other IFs (Morales et 
al., 2004). Among them, glucose was the major monosaccharide with highly variable 
contents. Regarding to fructose, only three samples showed contents higher than 0.1 g/100 
g, probably due to the presence of free fructose in the products with added FOS. The 
galactose content was higher than those found by Morales et al. (2004) and similar to those 
obtained by Troyano, Villamiel, Olano, Sanz and Martinez-Castro (1996) in commercial 
sterilized milks. Myo-inositol, a polyalcohol that may play a significant role in the 
prevention of bronchopulmonary dysplasia and retinopathy in premature infants (Hallman, 
Saugstad, Porreco, Epstein, & Gluck, 1985), was present in all IFs at concentrations 
significantly higher than those reported for Spanish commercial milks (Troyano et al., 
1996), but similar to the found by Woollard, Macfadzean, Indyk, McMahon and 
Christiansen (2014). As expected, with the exception of the lactose-free IFs, lactose was 
the main carbohydrate in all studied products, with amounts varying between 19.2 and 70.1 
g/100 g. Maltose was found in most of the analysed IFs in a range from 0.2 to 7 g/100 g. 
This compound is usually not added as ingredient in IFs and its presence may be related to 
the partial hydrolysis of the added maltodextrins during processing. Some low amounts of 
sucrose were found in the formulas enriched with FOS and in those enriched with 
GOS/FOS (0.13 – 0.19 and 0.01 – 0.05 g/100 g, respectively). Maltulose was also detected 
in five IFs in a range from 0.05 to 0.23 g/100 g (data not shown). This isomer of maltose 
was detected for the first time in IF by Morales et al. (2004), who found a wide variability 
from 0.13 to 0.8 g/100 g product, attributing this to differences in processing conditions.  
The analysis of maltodextrins by HPLC-RID allowed the quantitative determination 
of oligosaccharides with DP of up to 19. As it can be seen from the Table 3, maltodextrins 
were the second major component (after lactose) of most of the studied products with 
contents varying from 0.84 to 45.7 g/100 g of product. Among them, the most abundant 
compounds were those with DP between 3 and 6 (data not shown). 
In the IF containing prebiotic oligosaccharides the content of FOS and GOS were in 
the ranges of 1.6-5.0 and 1.7-3.2 g/100 g, respectively. In the products enriched with a 
mixture of FOS and GOS the content was in the range 0.08–0.25 and 2.3-3.8 g/100 g, 
respectively. Some of these values and especially those referred to the products enriched 
with FOS were below the officially declared values on the labels. These differences are 
probably due to the difficulties of quantification of oligosaccharides with a high DP 
(inulins), since it was specified on the label that these formula contained these 
polysaccharides. 
The analysed IFs presented prebiotic oligosaccharide contents in the range of 2.0 to 
6.4 g/L (considering IF reconstitution of 12.5% w/v). In Europe, IFs are supplemented with 
prebiotic oligosaccharides according to Directive 2006/141/CE, which allows addition of 
these carbohydrates in amounts of up to 8 g/L. Different studies have shown that this 
concentration limit is strictly respected and that the most commonly assayed prebiotics 
used in IFs are FOS, GOS and GOS/FOS mixtures (in a 9:1 ratio) at concentrations ranging 
between 1.5 - 8 g/L (Braegger et al., 2011). Several experimental studies have revealed that 
at these concentrations, prebiotics had a significant bifidogenic effect (Ben et al., 2008; 
Euler, Mitchell, Kline, & Pickering, 2005), modulates the intestinal flora and the immune 
system as human milk does (Fanaro et al., 2005) and provides beneficial effects for 
formula-fed infants (Boehm et al., 2005). Also, the amounts of prebiotics added to IF were 
generally well tolerated and they did not produce adverse side effects (crying, regurgitation 
or vomiting) (Boehm et al., 2002; Closa-Monasterolo et al., 2013). 
4. Conclusion 
This study shows that the analysed IFs present carbohydrate contents within the 
range indicated on the package labels. The combined utilization of GC and HPLC 
techniques allows an overall quantification of the carbohydrate fraction, including 
prebiotic oligosaccharides. GC-FID and HPLC-RID are rapid, simple, cheap, and powerful 
analytical techniques commonly found in academic and industrial laboratories. Beside, GC 
presents high resolving power, sensitivity and selectivity which enables the determination 
of higher oligosaccharides in foods that are often present at low concentrations.  
The results have demonstrated the usefulness of GC as a powerful tool for the 
analysis of mono-, and disaccharides, as well as GOS, FOS and their mixtures in IFs. 
Furthermore, the methodology proposed here may be used for routine quality control of IF 
and other food ingredients containing prebiotics.  
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Figure legends: 
Figure 1. GC-FID profiles of trimethylsilyl oximes (TMSO) of the carbohydrates present 
in (A): Commercial Vivinal®GOS (red) and infant formula with GOS (blue). Peaks:  1: 
Galactose, 2: Glucose, 3: Myo-inositol, I.S.: Internal standard (phenyl-β-D-glucoside), 4: 
Lactose, 5: 6-Galactobiose, 6: 4’Galactosyl-lactose, 7: 6’Galactosyl-lactose, 8: 
4’Digalactosyl-lactose; 9: 4’Trigalactosyl-lactose; and (B) Commercial Raftilose®FOS 
(red) and infant formula with FOS (blue). Peaks: 1: Fructose, 2: Galactose, 3: Glucose, 4: 
Myo-inositol, 5: Sucrose, 6: Lactose, 7: Maltose, 8: Kestose, 9: Trifructosaccharides, 10: 
Maltotriose, 11: Nystose, 12: Tetrafructosaccharides, 13: Maltotetraose, 14: Fructosyl-
nystose, 15: Pentafructosaccharides, 16: Maltopentaose, 17: Difructosyl-nystose, 18: 
Hexafructosaccharides, 19: Trifructosyl-nystose, 20: Heptafructosaccharides. DP: Degree 
of polymerisation. 
 
Figure 2. GC-FID profile of TMSO derivatives of carbohydrates present in a commercial 
infant formulas with maltodextrins and GOS before (blue) and after (red) of α-
amyloglucosidase treatment. (1) GOS; (2) Maltodextrins. DP: Degree of polymerisation. 
 
Figure 1A. 
Figure 1B 
 
Figure 2 
 
Table 1. Carbohydrate composition of infant formulas available at the Spanish market, 
according to their package labels. 
Product 
 code 
Total 
carbohydrates Lactose Prebiotics Maltodextrins Inositol  
 
 
Observations
(g/100 g product)  (mg/100 g) 
 
  
 
Infant formula without prebiotics 
   
 
Conventional (C) 
         
C1 57.8 57.8 80.0 
C2 61.7 - 1 - -  mdx 
C3 60.0 - 12.3 -  starch 
C4 55.6 - - 9.9  mdx 
 
Lactose free (LF) 
         
LF1 58.6   - 36.0  mdx  
LF2 60.8   60.8 9.9  mdx 
LF3 57.6 36.1 47.0  mdx 
LF4 55.0 - 30.0  mdx 
 
Infant formula with prebiotics 
   
 
With fructooligosaccharides (PFOS) 
     
PFOS1 53.3 - 5.7 - 45.0 FOS/inuline 
PFOS2 56.0 - 3.0 - 45.0 FOS/inuline 
PFOS3 50.8 5.7 50.8 25.0 without lactose 
 
With galactooligosaccharides  (PGOS)     
PGOS1 50.1 46.0 3.5 2.52 32.0  GOS 
PGOS2 55.0 -  1.5 1.5 51.0 GOS.mdx3,4 
PGOS3 62.9 - 2.2 - 25.0 GOS.mdx 
PGOS4 56.4 - 1.9 - 30.0 GOS.mdx 
PGOS5 61.7 - 2.6 - 26.0 GOS.mdx 
PGOS6 55.6 35.6 2.5 19.4 24.4 GOS.mdx 
PGOS7 50.9 45.3 2.8 5.0 27.2 GOS.mdx 
 
With galactooligosaccharides and fructooligosaccharides (PGOS/FOS) 
 
PGOS/FOS1 59.0 56.5 3.9 25.0 GOS/FOS 
PGOS/FOS2 59.3 41.9 3.8 - 24.7 GOS/FOS.mdx4
PGOS/FOS3 59.3 41.9 3.8 - 24.7 GOS/FOS.mdx 
PGOS/FOS4 59.3 41.9 3.8 - 24.7 GOS/FOS.mdx 
PGOS/FOS5 55.7 19.7 3.8 - 23.0 GOS/FOS.mdx 
PGOS/FOS6 53.6 - 2.9 - - GOS/FOS.mdx 
 
1 The data did not appear on the label;  2 High molecular mass dextrin;  3  mdx: maltodextrins; 
4Infant formula containing GOS.mdx and GOS/FOS.mdx were  treated with α-amyloglucosidase.  
Table 2. Repeatability of the used GC method for determination of carbohydrates in a 
commercial infant formula containing prebiotics, prepared four times and analysed on 
the same day and on different days (four days). 
 
 
 Concentration (mg/100 g of product) 
Carbohydrate Same day   (four replicates) 
Daily (during 4 days)  
(one replicate) 
 Averagevalue RSD* (%)
Average 
value RSD (%) 
 
Fructose 0.33 4.4 0.33 4.6 
Galactose 0.02 8.3 0.02 8.8 
Glucose 0.18 4.7 0.19 5.3 
Myo-inositol 0.06 4.3 0.05 4.5 
Sucrose 0.18 5.6 0.17 4.4 
Lactose 41.61 3.9 41.7 3.6 
Maltose 0.30 7.3 0.32 6.8 
Trisaccharides 0.60 6.3 0.59 7.3 
Tetrasaccharides 0.59 7.3 0.56 7.6 
Pentasaccharides 0.25 6.9 0.27 7.4 
Hexa and heptasaccharides 0.26 9.9 0.23 12.3 
 
*RSD: relative standard deviation 
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1Values obtained by HPLC analysis.  32 
2TCH: Total carbohydrates. Each value is the sum of fructose, galactose, glucose, myo-inositol, sucrose, lactose, maltose, GOS, FOS and  maltodextrins (DP 3-19). 33 
Product code: like in table 1. 34 
Product 
code Fructose Galactose Glucose Myo-inositol Sucrose Lactose Maltose GOS FOS Maltodextrins (DP 3-19)
1 TCH2 
C1 0.21 ± 0.00 0.27 ± 0.01 0.07 ± 0.00 70.1 ± 1.2 70.77 
C2 0.02 ± 0.00 0.25 ± 0.01 0.39 ± 0.02 0.03 ± 0.00 30.7 ± 1.7 1.43 ± 0.06 11.7 ± 2.7 44.62 
C3 0.01 ± 0.00 0.26 ± 0.00 0.15 ± 0.00 0.05 ± 0.00. 45.5 ± 0.3 0.20 ± 0.00 0.8 ± 0.2 46.96 
C4 0.05 ± 0.00 0.05 ± 0.00 1.59 ± 0.04 0.08 ± 0.01 22.2 ± 0.6 4.98 ± 0.11 22.5 ± 0.2 51.53 
LF1 0.05 ± 0.00  1.27 ± 0.04 0.01 ± 0.00 5.73 ± 0.20 41.0 ± 0.6 48.14 
LF2 0.04 ± 0.00 0.07 ± 0.00 0.99 ± 0.00 0.01 ± 0.00 3.01 ± 0.01 27.8 ± 5.7 31.88 
LF3 0.03 ± 0.00 3.96 ± 0.04 0.03 ± 0.00 7.02 ± 0.05 45.7 ± 2.1 56.84 
LF4 0.03 ± 0.00 1.53 ± 0.01 0.03 ± 0.00 5.11 ± 0.01 30.1 ± 1.6 36.85 
PFOS1 0.34 ± 0.17 0.02 ± 0.00 0.19 ± 0.10 0.05 ± 0.00 0.17 ± 0.06 41.6 ± 1.7 0.30 ± 0.03 1.75 ± 0.07 4.3 ± 0.5 48.74 
PFOS2 0.13 ± 0.01 0.08 ± 0.00 0.17 ± 0.01 0.06 ± 0.00 0.13 ± 0.01 47.5 ± 2.7 0.37 ± 0.00 1.57 ± 0.06 5.3 ± 0.7 55.27 
PFOS3 0.05 ± 0.00 0.13 ± 0.01 0.69 ± 0.03 0.03 ± 0.00 0.19 ± 0.01 2.87 ± 0.13 5.00 ± 0.25 35.9 ± 0.2 44.90 
PGOS1 0.03 ± 0.01 0.16 ± 0.01 1.29 ± 0.04 0.05 ± 0.00 44.5 ± 1.0 0.39 ± 0.01 3.16 ± 0.14 49.58 
PGOS2 0.03 ± 0.00 0.23 ± 0.01 0.92 ± 0.02 0.06 ± 0.00 45.2 ± 0.9 0.32 ± 0.01 1.70 ± 0.04 1.7 ± 0.3 50.18 
PGOS3 0.04 ± 0.00 0.13 ± 0.00 1.16 ± 0.00 0.04 ± 0.00 38.5 ± 0.0 1.57 ± 0.02 2.24 ± 0.05 11.3 ± 0.7 55.05 
PGOS4 0.03 ± 0.00 0.12 ± 0.02 0.81 ± 0.09 0.04 ± 0.00 49.1 ± 0.0 0.54 ± 0.07 1.86 ± 0.14 2.3 ± 0.1 54.80 
PGOS5 0.03 ± 0.00 0.15 ± 0.01 1.28 ± 0.13 0.04 ± 0.00 36.4 ± 3.5 1.57 ± 0.17 2.35 ± 0.05 11.1 ± 0.3 52.9 
PGOS6 0.05 ± 0.00 0.13 ± 0.01 1.09 ± 0.09 0.02 ± 0.00 35.0 ± 3.1 0.82 ± 0.09 2.39 ± 0.07 14.5 ± 1.9 53.99 
PGOS7 0.05 ± 0.00 0.16 ± 0.00 1.34 ± 0.02 0.05 ± 0.00 46.3 ± 3.2 0.72 ± 0.02 2.68 ± 0.14 4.2 ± 0.7 55.49 
PGOS/FOS1 0.03 ± 0.00 0.12 ± 0.01 1.59 ± 0.14 0.03 ± 0.01 0.01 ± 0,00 51.1 ± 4.0 3.67 ± 0.11 0.13 ± 0.02 56.70 
PGOS/FOS2 0.04 ± 0.00 0.20 ± 0.04 1.83 ± 0.16 0.04 ± 0.00 0.01 ± 0.00 39.9 ± 3.8 1.28 ± 0.24 3.73 ± 0.16 0.16 ± 0.00 26.2 ± 2.3 73.39 
PGOS/FOS3 0.16 ± 0.21 0.17 ± 0.01 0.64 ± 0.14 0.03 ± 0.00 0.05 ± 0.05 38.5 ± 2.0 1.14 ± 0.12 3.64 ± 0.18 0.13 ± 0.01 15.0 ± 1.8 60.09 
PGOS/FOS4 0.03 ± 0.00 0.12 ± 0.01 1.60 ± 0.16 0.03 ± 0.00 0.01 ± 0.00 33.9 ± 3.1 1.22 ± 0.09 3.79 ± 0.15 0.09 ± 0.00 11.1 ± 0.3 52.40 
PGOS/FOS5 0.07 ± 0.01 0.18 ± 0.01 2.06 ± 0.10 0.03 ± 0.00 0.01 ± 0.00 19.2 ± 0.9 2.15 ± 0.11 3.70 ± 0.03 0.08 ± 0.01 19.4 ± 2.3 46.81 
PGOS/FOS6 0.04 ± 0.00 0.11 ± 0.00 1.22 ± 0.02 0.07 ± 0.00 0.04 ± 0.00 29.5 ± 0.6 1.69 ± 0.03 2.28 ± 0.20 0.25 ± 0.05 21.5 ± 1.7 56.74 
